Eyepoint Pharmaceuticals, INC 8-K filings

EyePoint, Inc. announced its second quarter 2026 financial results, highlighting progress in its DURAVYU clinical trials for wet AMD and DME, with topline data expected soon and a cash runway extending into late 2027.

EyePoint, Inc. announced the completion of enrollment in its pivotal Phase 3 clinical trials for DURAVYU in treating diabetic macular edema (DME), with topline data expected in Q4 2027.

EyePoint, Inc. has entered into a settlement agreement with the U.S. Department of Justice to resolve allegations related to past sales and marketing practices for DEXYCU, agreeing to pay $4.7 million and enter a five-year Corporate Integrity Agreement.

EyePoint announced a positive third consecutive recommendation from its Data Safety Monitoring Committee for the ongoing Phase 3 trials of DURAVYU in wet AMD, reinforcing confidence ahead of mid-2026 topline data.

EyePoint announced its first quarter 2026 financial results, highlighting progress in its Phase 3 wet AMD and DME clinical trials, with significant cash reserves extending runway into late 2027.

EyePoint, Inc. has released an updated investor presentation detailing the progress of its investigational drug DURAVYU for retinal diseases, including anticipated timelines for clinical data and manufacturing updates.

EyePoint, Inc. has filed a lawsuit against Ocular Therapeutix, Inc., alleging defamation and commercial disparagement regarding its lead product candidate, DURAVYU.

EyePoint, Inc. announced its fourth quarter and full-year 2025 financial results, highlighting significant progress in its DURAVYU clinical programs for wet AMD and DME, alongside a strong cash position.

EyePoint, Inc. announced the dosing of the first patients in its global Phase 3 clinical trials, COMO and CAPRI, for DURAVYU (vorolanib intravitreal insert) in diabetic macular edema (DME).

EyePoint, Inc. provides a corporate update, highlighting progress in its DURAVYU Phase 3 trials for wet AMD and DME, and reports a strong cash position of approximately $300 million.

EyePoint Pharmaceuticals, Inc. officially changed its corporate name to EyePoint, Inc., effective December 8, 2025, with no impact on its Nasdaq ticker symbol EYPT or shareholder rights.

EyePoint Pharmaceuticals announced a positive recommendation from its independent Data Safety Monitoring Committee for its pivotal Phase 3 program evaluating DURAVYU for wet age-related macular degeneration.

EyePoint Pharmaceuticals filed a prospectus supplement for an at-the-market offering of up to $200 million in common stock.

EyePoint Pharmaceuticals announced its third quarter 2025 financial results, highlighted progress in its DURAVYU clinical trials for wet AMD and DME, and confirmed funding into Q4 2027.

EyePoint Pharmaceuticals, Inc. announced the pricing of a public offering of common stock and pre-funded warrants, raising approximately $141 million to fund clinical development of DURAVYU and pipeline initiatives.

EyePoint Pharmaceuticals announces the initiation of its pivotal Phase 3 program for DURAVYU in diabetic macular edema, supported by new multi-mechanism of action data.

EyePoint Pharmaceuticals announced rapid enrollment completion for its pivotal wet AMD trials and initiated manufacturing, despite reporting increased Q2 2025 net loss and reduced revenue.

EyePoint Pharmaceuticals has successfully completed enrollment for both pivotal Phase 3 clinical trials, LUGANO and LUCIA, evaluating DURAVYU for wet age-related macular degeneration, ahead of schedule.

EyePoint Pharmaceuticals announced the successful and early completion of enrollment for its pivotal Phase 3 LUCIA trial, marking the full enrollment of its DURAVYU program for wet age-related macular degeneration.

EyePoint Pharmaceuticals, Inc. announced that its stockholders approved an amendment to increase shares available under its long-term incentive plan by 2.9 million, re-elected all directors, and ratified executive compensation and auditor appointment at its 2025 Annual Meeting.

EyePoint Pharmaceuticals, Inc. announced the completion of enrollment for its pivotal Phase 3 LUGANO trial for DURAVYU in wet age-related macular degeneration (wet AMD), significantly ahead of schedule, with topline data expected in mid-2026.

EyePoint Pharmaceuticals announces promising enrollment progress in its DURAVYU Phase 3 wet AMD clinical trials and reports its first quarter 2025 financial results, highlighting a strong cash position.

EyePoint Pharmaceuticals announces positive Phase 2 VERONA trial results for DURAVYU in DME and provides a financial update, highlighting a strong cash position and progress in Phase 3 wet AMD trials.

EyePoint Pharmaceuticals highlights positive clinical trial results for DURAVYU in wet AMD and DME, a strong financial position, and ongoing progress in its pipeline at the TD Cowen Healthcare Conference.

EyePoint Pharmaceuticals reports positive six-month results from its Phase 2 VERONA trial of DURAVYU for diabetic macular edema, meeting primary and secondary endpoints.

EyePoint Pharmaceuticals reports positive progress in its Phase 3 clinical trials for DURAVYU in wet AMD and anticipates full data from its Phase 2 trial in DME, along with a strong cash position and new board member.

EyePoint Pharmaceuticals has appointed Dr. Reginald Sanders, a renowned retina specialist, to its Board of Directors, effective January 8, 2025.

EyePoint Pharmaceuticals has announced the dosing of the first patient in its second global Phase 3 clinical trial, LUCIA, for its investigational wet AMD treatment, DURAVYU.

EyePoint Pharmaceuticals reported positive interim data for its DURAVYU treatment in diabetic macular edema (DME), dosed the first patient in a Phase 3 trial for wet AMD, and secured $161 million in an equity financing.

EyePoint Pharmaceuticals successfully closed a public offering of common stock, raising approximately $161 million after the underwriters fully exercised their option to purchase additional shares.